MARKET

OCUL

OCUL

Ocular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.300
-0.010
-0.23%
After Hours: 4.300 0 0.00% 16:00 09/18 EDT
OPEN
4.320
PREV CLOSE
4.310
HIGH
4.340
LOW
4.180
VOLUME
305.83K
TURNOVER
--
52 WEEK HIGH
7.31
52 WEEK LOW
2.350
MARKET CAP
202.94M
P/E (TTM)
-2.4118
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OCUL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OCUL News

  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS
  • ACCESSWIRE.09/03 21:15
  • Ocular Therapeutix to Present at the 2019 Wells Fargo Healthcare Conference
  • Business Wire.08/29 13:00
  • Ocular Therapeutix: A Diamond In The Rough As Dextenza Is Finally Launching With The Right Attributes For Success
  • Seeking Alpha - Article.08/27 13:00
  • 50 Biggest Movers From Yesterday
  • Benzinga.08/27 09:20

More

Industry

Medical Equipment, Supplies & Distribution
-0.01%
Healthcare Equipment & Supplies
+0.17%

Hot Stocks

Name
Price
%Change

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
More

Webull offers Ocular Therapeutix Inc (OCUL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.